Nucleotide analogs
Approved
Nucleotide analogs is one of 4 therapeutic programs targeting Chronic Hepatitis b. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Chronic Hepatitis B
#DrugCompanyPhaseTrials
1PEG-IFNα
GileadApproved
Bepirovirsen
GSKPhase 3
Anti-PD-L1 Antibody
LLee's Pharmaceutical Limited
Approved
Nucleotide analogs
TThe Second Affiliated Hospital of Chongqing Medical University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis b1 trial
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·150 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Nucleotide analogs. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]